H.R.4117: Competitive DRUGS Act of 2017
Author's Summary: To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes.
IB Summary: Drug prices can cost prohibitive for many patients - this bill hopes to lower those costs by getting generic drugs on the market as quick as possible.
Status: Introduced on 10/25/2017. Referred to the Committee on Ways and Means, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.